4-isopropyl-5-methyl-2-phenyloxazole | 34699-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-isopropyl-5-methyl-2-phenyloxazole
• 英文别名: 5-Methyl-4-isopropyl-2-phenyloxazol；5-Methyl-2-phenyl-4-propan-2-yl-1,3-oxazole
• CAS: 34699-10-0
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: UGKFUPRSIMPSFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-Acetyl-4-isopropyl-2-phenyl-2-oxazolin-5-on 反应 0.17h， 生成 4-isopropyl-5-methyl-2-phenyloxazole
  参考文献：
  名称：

  Hoefle,G.; Steglich,W., Chemische Berichte, 1971, vol. 104, p. 1408 - 1419

  摘要：

  DOI：

文献信息

• Synthesis of Substituted Oxazoles from<i>N</i>-Benzyl Propargyl Amines and Acid Chlorides
  作者：Henrik v. Wachenfeldt、Filip Paulsen、Anders Sundin、Daniel Strand

  DOI：10.1002/ejoc.201300285

  日期：2013.7

  The reaction between N-benzylpropargylamines and acid chlorides at elevated temperatures provides efficient, direct access to a variety of di- and tri-substituted oxazoles. The versatility of this reaction is explored and 21 examples are demonstrated. The usefulness of the methodology is showcased through the short and efficient formal syntheses of medicinally relevant drugs aleglitazar and romazarit

  N-苄基炔丙基胺和酰氯在高温下的反应提供了有效、直接获得各种二取代和三取代恶唑的途径。探索了该反应的多功能性，并展示了 21 个例子。该方法的实用性通过药用相关药物 aleglitazar 和 romazarit 的简短而有效的正式合成得到展示。
• BENZYLAMINE DERIVATIVES
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20160039752A1

  公开（公告）日：2016-02-11

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了式(I)的化合物：包括这些化合物的组合物；使用这些化合物进行治疗（例如在涉及血浆卡利肌酶活性的疾病或病症的治疗或预防中）；以及使用这些化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z的定义如本文所述。
• INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160145251A1

  公开（公告）日：2016-05-26

  Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

  本文披露了抑制由肌动蛋白相关转录因子和血清反应因子或肌动蛋白相关转录因子和血清反应因子（“MRTF / SRF”）介导的基因转录的抑制剂，以及它们在治疗或预防癌症和纤维化方面的使用方法。特别地，本文披露了公式（I）和公式（II）的化合物及其药学上可接受的盐：其中取代基如所述。
• Jendrzejewski, Stefan; Steglich, Wolfgang, Chemische Berichte, 1981, vol. 114, # 4, p. 1337 - 1342
  作者：Jendrzejewski, Stefan、Steglich, Wolfgang

  DOI：——

  日期：——
• Benzylamine Derivatives
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20170253561A1

  公开（公告）日：2017-09-07

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.